71 related articles for article (PubMed ID: 20629032)
21. Expression of c-ABL, c-KIT, and platelet-derived growth factor receptor-beta in ovarian serous carcinoma and normal ovarian surface epithelium.
Schmandt RE; Broaddus R; Lu KH; Shvartsman H; Thornton A; Malpica A; Sun C; Bodurka DC; Gershenson DM
Cancer; 2003 Aug; 98(4):758-64. PubMed ID: 12910520
[TBL] [Abstract][Full Text] [Related]
22. Inhibitory effect of STI571 on cell proliferation of human malignant fibrous histiocytoma cell lines.
Kawamoto T; Akisue T; Marui T; Nakatani T; Hitora T; Fujita I; Kurosaka M; Yamamoto T
Anticancer Res; 2004; 24(5A):2675-9. PubMed ID: 15517872
[TBL] [Abstract][Full Text] [Related]
23. C6-unsubstituted pyrazolo[3,4-d]pyrimidines are dual Src/Abl inhibitors effective against imatinib mesylate resistant chronic myeloid leukemia cell lines.
Santucci MA; Corradi V; Mancini M; Manetti F; Radi M; Schenone S; Botta M
ChemMedChem; 2009 Jan; 4(1):118-26. PubMed ID: 19039816
[TBL] [Abstract][Full Text] [Related]
24. Kit and PDGFR-alpha activities are necessary for Notch4/Int3-induced tumorigenesis.
Raafat A; Zoltan-Jones A; Strizzi L; Bargo S; Kimura K; Salomon D; Callahan R
Oncogene; 2007 Feb; 26(5):662-72. PubMed ID: 16878155
[TBL] [Abstract][Full Text] [Related]
25. Activated c-Abl tyrosine kinase in malignant solid tumors.
Lin J; Arlinghaus R
Oncogene; 2008 Jul; 27(32):4385-91. PubMed ID: 18391983
[TBL] [Abstract][Full Text] [Related]
26. Alpha-internexin expression in medulloblastomas and atypical teratoid-rhabdoid tumors.
Kaya B; Mena H; Miettinen M; Rushing EJ
Clin Neuropathol; 2003; 22(5):215-21. PubMed ID: 14531545
[TBL] [Abstract][Full Text] [Related]
27. Atypical teratoid rhabdoid tumors of childhood: diagnosis, treatment and challenges.
Strother D
Expert Rev Anticancer Ther; 2005 Oct; 5(5):907-15. PubMed ID: 16221059
[TBL] [Abstract][Full Text] [Related]
28. Activation of c-Abl tyrosine kinase requires caspase activation and is not involved in JNK/SAPK activation during apoptosis of human monocytic leukemia U937 cells.
Dan S; Naito M; Seimiya H; Kizaki A; Mashima T; Tsuruo T
Oncogene; 1999 Feb; 18(6):1277-83. PubMed ID: 10022809
[TBL] [Abstract][Full Text] [Related]
29. Disrupting LIN28 in atypical teratoid rhabdoid tumors reveals the importance of the mitogen activated protein kinase pathway as a therapeutic target.
Weingart MF; Roth JJ; Hutt-Cabezas M; Busse TM; Kaur H; Price A; Maynard R; Rubens J; Taylor I; Mao XG; Xu J; Kuwahara Y; Allen SJ; Erdreich-Epstein A; Weissman BE; Orr BA; Eberhart CG; Biegel JA; Raabe EH
Oncotarget; 2015 Feb; 6(5):3165-77. PubMed ID: 25638158
[TBL] [Abstract][Full Text] [Related]
30. The TORC1/2 inhibitor TAK228 sensitizes atypical teratoid rhabdoid tumors to cisplatin-induced cytotoxicity.
Rubens JA; Wang SZ; Price A; Weingart MF; Allen SJ; Orr BA; Eberhart CG; Raabe EH
Neuro Oncol; 2017 Oct; 19(10):1361-1371. PubMed ID: 28582547
[TBL] [Abstract][Full Text] [Related]
31. MEK Inhibition Suppresses Growth of Atypical Teratoid/Rhabdoid Tumors.
Shahab S; Rubens J; Kaur H; Sweeney H; Eberhart CG; Raabe EH
J Neuropathol Exp Neurol; 2020 Jul; 79(7):746-753. PubMed ID: 32472116
[TBL] [Abstract][Full Text] [Related]
32. Targeting Aurora Kinase A enhances radiation sensitivity of atypical teratoid rhabdoid tumor cells.
Venkataraman S; Alimova I; Tello T; Harris PS; Knipstein JA; Donson AM; Foreman NK; Liu AK; Vibhakar R
J Neurooncol; 2012 May; 107(3):517-26. PubMed ID: 22246202
[TBL] [Abstract][Full Text] [Related]
33. High-Throughput Drug Screening Identifies Pazopanib and Clofilium Tosylate as Promising Treatments for Malignant Rhabdoid Tumors.
Chauvin C; Leruste A; Tauziede-Espariat A; Andrianteranagna M; Surdez D; Lescure A; Han ZY; Anthony E; Richer W; Baulande S; Bohec M; Zaidi S; Aynaud MM; Maillot L; Masliah-Planchon J; Cairo S; Roman-Roman S; Delattre O; Del Nery E; Bourdeaut F
Cell Rep; 2017 Nov; 21(7):1737-1745. PubMed ID: 29141209
[TBL] [Abstract][Full Text] [Related]
34. Small-Molecule and CRISPR Screening Converge to Reveal Receptor Tyrosine Kinase Dependencies in Pediatric Rhabdoid Tumors.
Oberlick EM; Rees MG; Seashore-Ludlow B; Vazquez F; Nelson GM; Dharia NV; Weir BA; Tsherniak A; Ghandi M; Krill-Burger JM; Meyers RM; Wang X; Montgomery P; Root DE; Bieber JM; Radko S; Cheah JH; Hon CS; Shamji AF; Clemons PA; Park PJ; Dyer MA; Golub TR; Stegmaier K; Hahn WC; Stewart EA; Schreiber SL; Roberts CWM
Cell Rep; 2019 Aug; 28(9):2331-2344.e8. PubMed ID: 31461650
[TBL] [Abstract][Full Text] [Related]
35. Design, synthesis of novel peptidomimetic derivatives of 4-HPR for rhabdoid tumors.
Das BC; Smith ME; Kalpana GV
Bioorg Med Chem Lett; 2008 Jul; 18(14):4177-80. PubMed ID: 18556204
[TBL] [Abstract][Full Text] [Related]
36. Rhabdoid tumor of the kidney in an adult: review of the literature and report of a case responding to interleukin-2.
Ebbinghaus SW; Herrera G; Marshall ME
Cancer Biother; 1995; 10(3):237-41. PubMed ID: 8547962
[TBL] [Abstract][Full Text] [Related]
37. DisABLing kidney cancers caused by fumarate hydratase mutations.
Kaelin WG
Cancer Cell; 2014 Dec; 26(6):779-780. PubMed ID: 25490441
[TBL] [Abstract][Full Text] [Related]
38. Suboccipital Extraspinal Extracranial Atypical Teratoid Rhabdoid Tumor.
Karthikeyan YR; Gupta A; Varshney T; Deora APS
J Neurosci Rural Pract; 2017; 8(3):494-495. PubMed ID: 28694650
[No Abstract] [Full Text] [Related]
39. Corrigendum to: Molecular subgrouping of atypical teratoid/rhabdoid tumors-a reinvestigation and current consensus.
Ho B; Johann PD; Grabovska Y; De Dieu Andrianteranagna MJ; Yao FP; Frühwald M; Hasselblatt M; Bourdeaut F; Williamson D; Huang A; Kool M
Neuro Oncol; 2022 Jul; 24(7):1213. PubMed ID: 33283872
[No Abstract] [Full Text] [Related]
40. Multimodal management of locally advanced rhabdoid tumour of the kidney in an adult.
Goel R; Panaiyadiyan S; Nayak B; Singh P
BMJ Case Rep; 2021 Apr; 14(4):. PubMed ID: 33846176
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
